|
1
|
Gusyatiner O and Hegi ME: Glioma
epigenetics: From subclassification to novel treatment options.
Semin Cancer Biol. 51:50–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohgaki H and Kleihues P: Epidemiology and
etiology of gliomas. Acta Neuropathol. 109:93–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang Q, Zhou Y, Chen J, Huang N, Wang Z
and Cheng Y: Gene therapy for drug-resistant glioblastoma via
lipid-polymer hybrid nanoparticles combined with focused
ultrasound. Int J Nanomedicine. 16:185–199. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li X, Deng Y, Zheng Z, Huang W, Chen L,
Tong Q and Ming Y: Corilagin, a promising medicinal herbal agent.
Biomed Pharmacother. 99:43–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu C, Huang H, Choi HY, Ma Y, Zhou T, Peng
Y, Pang K, Shu G and Yang X: Anti-esophageal cancer effect of
corilagin extracted from phmllanthi fructus via the mitochondrial
and endoplasmic reticulum stress pathways. J Ethnopharmacol.
269:1137002021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wan LF, Shen JJ, Wang YH, Zhao W, Fang NY,
Yuan X and Xue BY: Extracts of Qizhu decoction inhibit hepatitis
and hepatocellular carcinoma in vitro and in C57BL/6 mice by
suppressing NF-κB signaling. Sci Rep. 9:14152019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qiu F, Liu L, Lin Y, Yang Z and Qiu F:
Corilagin inhibits esophageal squamous cell carcinoma by inducing
DNA damage and down-regulation of RNF8. Anticancer Agents Med Chem.
19:1021–1028. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tong Y, Zhang G, Li Y, Xu J, Yuan J, Zhang
B, Hu T and Song G: Corilagin inhibits breast cancer growth via
reactive oxygen species-dependent apoptosis and autophagy. J Cell
Mol Med. 22:3795–3807. 2018. View Article : Google Scholar
|
|
10
|
Iweala EEJ, Xu J, Zhang G, Tong Y, Yuan J,
Li Y and Song G: Corilagin induces apoptosis, autophagy and ROS
generation in gastric cancer cells in vitro. Int J Mol Med.
43:967–979. 2019.PubMed/NCBI
|
|
11
|
Yang WT, Li GH, Li ZY, Feng S, Liu XQ, Han
GK, Zhang H, Qin XY, Zhang R, Nie QM and Jin F: Effect of corilagin
on the proliferation and NF-κB in U251 glioblastoma cells and U251
glioblastoma stem-like Cells. Evid Based Complement Alternat Med.
2016:14183092016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Milani R, Brognara E, Fabbri E, Finotti A,
Borgatti M, Lampronti I, Marzaro G, Chilin A, Lee KK, Kok SH, et
al: Corilagin induces high levels of apoptosis in the
temozolomide-resistant T98G glioma cell line. Oncol Res.
26:1307–1315. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee J, Kim J, Kim EM, Kim U, Kang AR, Park
JK and Um HD: p21WAF1/CIP1 promotes p53 protein
degradation by facilitating p53-Wip1 and p53-Mdm2 interaction.
Biochem Biophys Res Commun. 543:23–28. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sakata E, Eisele MR and Baumeister W:
Molecular and cellular dynamics of the 26S proteasome. Biochim
Biophys Acta Proteins Proteom. 1869:1405832021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bard JAM, Goodall EA, Greene ER, Jonsson
E, Dong KC and Martin A: Structure and function of the 26S
proteasome. Annu Rev Biochem. 87:697–724. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Murata S, Takahama Y, Kasahara M and
Tanaka K: The immunoproteasome and thymoproteasome: Functions,
evolution and human disease. Nat Immunol. 19:923–931. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rousseau A and Bertolotti A: Regulation of
proteasome assembly and activity in health and disease. Nat Rev Mol
Cell Biol. 19:697–712. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ettari R, Pallio G, Pizzino G, Irrera N,
Zappalà M, Maiorana S, Di Chio C, Altavilla D, Squadrito F and
Bitto A: Non-covalent immunoproteasome inhibitors induce cell cycle
arrest in multiple myeloma MM.1R cells. J Enzyme Inhib Med Chem.
34:1307–1313. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kuzina ES, Kudriaeva AA, Maltseva DV and
Belogurov AA Jr: Peptidyl aldehyde specifically interacts with
immunosubunit β1i proteasome: In vitro and in vivo effects. Bull
Exp Biol Med. 161:69–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun C, Mo M, Wang Y, Yu W, Song C, Wang X,
Chen S and Liu Y: Activation of the immunoproteasome protects
SH-SY5Y cells from the toxicity of rotenone. Neurotoxicology.
73:112–119. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vilchez D, Boyer L, Morantte I, Lutz M,
Merkwirth C, Joyce D, Spencer B, Page L, Masliah E, Berggren WT, et
al: Increased proteasome activity in human embryonic stem cells is
regulated by PSMD11. Nature. 489:304–308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Toste Rêgo A and da Fonseca PCA:
Characterization of fully recombinant human 20S and 20S-PA200
proteasome complexes. Mol Cell. 76:138–147.e5. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanssum A, Zhong Z, Rousseau A, Krzyzosiak
A, Sigurdardottir A and Bertolotti A: An inducible chaperone adapts
proteasome assembly to stress. Mol Cell. 55:566–577. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Collins GA and Goldberg AL: The logic of
the 26S proteasome. Cell. 169:792–806. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kuo CL and Goldberg AL: Ubiquitinated
proteins promote the association of proteasomes with the
deubiquitinating enzyme Usp14 and the ubiquitin ligase Ube3c. Proc
Natl Acad Sci USA. 114:E3404–E3413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lokireddy S, Kukushkin NV and Goldberg AL:
cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11
enhances their activity and the degradation of misfolded proteins.
Proc Natl Acad Sci USA. 112:E7176–E7185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Myeku N, Clelland CL, Emrani S, Kukushkin
NV, Yu WH, Goldberg AL and Duff KE: Tau-driven 26S proteasome
impairment and cognitive dysfunction can be prevented early in
disease by activating cAMP-PKA signaling. Nat Med. 22:46–53. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Min L, Zeng X, Li B, Tao B, Shi J, Zhang
W, Sun Q, Jing C and Wang X: Overexpression of immunoproteasome
low-molecular-mass polypeptide 7 and inhibiting role of
next-generation proteasome inhibitor ONX 0912 on cell growth in
glioma. Neuroreport. 30:1031–1038. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qin XY, Zhang YL, Chi YF, Yan B, Zeng XJ,
Li HH and Liu Y: Angiotensin II regulates Th1 T cell
differentiation through angiotensin II type 1 receptor-PKA-mediated
activation of proteasome. Cell Physiol Biochem. 45:1366–1376. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ettari R, Previti S, Bitto A, Grasso S and
Zappalà M: Immunoproteasome-selective inhibitors: A promising
strategy to treat hematologic malignancies, autoimmune and
inflammatory diseases. Curr Med Chem. 23:1217–1238. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Welk V, Coux O, Kleene V, Abeza C,
Trümbach D, Eickelberg O and Meiners S: Inhibition of proteasome
activity induces formation of alternative proteasome complexes. J
Biol Chem. 291:13147–13159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mannhaupt G, Schnall R, Karpov V, Vetter I
and Feldmann H: Rpn4p acts as a transcription factor by binding to
PACE, a nonamer box found upstream of 26S proteasomal and other
genes in yeast. FEBS Lett. 450:27–34. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zarfati M, Avivi I, Brenner B, Katz T and
Aharon A: Extracellular vesicles of multiple myeloma cells utilize
the proteasome inhibitor mechanism to moderate endothelial
angiogenesis. Angiogenesis. 22:185–196. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Park JE, Miller Z, Jun Y, Lee W and Kim
KB: Next-generation proteasome inhibitors for cancer therapy.
Transl Res. 198:1–16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huber EM, Basler M, Schwab R, Heinemeyer
W, Kirk CJ, Groettrup M and Groll M: Immuno- and constitutive
proteasome crystal structures reveal differences in substrate and
inhibitor specificity. Cell. 148:727–738. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Muchamuel T, Basler M, Aujay MA, Suzuki E,
Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, et al: A
selective inhibitor of the immunoproteasome subunit LMP7 blocks
cytokine production and attenuates progression of experimental
arthritis. Nat Med. 15:781–787. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yoo YD, Lee DH, Cha-Molstad H, Kim H, Mun
SR, Ji C, Park SH, Sung KS, Choi SA, Hwang J, et al: Glioma-derived
cancer stem cells are hypersensitive to proteasomal inhibition.
EMBO Rep. 18:150–168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Su L, Guo W, Lou L, Nie S, Zhang Q, Liu Y,
Chang Y, Zhang X, Li Y and Shen H: EGFR-ERK pathway regulates CSN6
to contribute to PD-L1 expression in glioblastoma. Mol Carcinog.
59:520–532. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang XF, Zhao ZJ, Liu JJ, Yang XH, Gao Y,
Zhao S, Shi S, Huang KQ and Zheng HC: SAHA and/or MG132 reverse the
aggressive phenotypes of glioma cells: An in vitro and vivo study.
Oncotarget. 8:3156–3169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tang JH, Yang L, Chen JX, Li QR, Zhu LR,
Xu QF, Huang GH, Zhang ZX, Xiang Y, Du L, et al: Bortezomib
inhibits growth and sensitizes glioma to temozolomide (TMZ) via
down-regulating the FOXM1-Survivin axis. Cancer Commun (Lond).
39:812019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang M, Lu L, Ying M, Ruan H, Wang X,
Wang H, Chai Z, Wang S, Zhan C, Pan J and Lu W: Enhanced
Glioblastoma targeting ability of carfilzomib enabled by a
DA7R-modified lipid nanodisk. Mol Pharm. 15:2437–2447. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kong XT, Nguyen NT, Choi YJ, Zhang G,
Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, et al:
Phase 2 study of bortezomib combined with temozolomide and regional
radiation therapy for upfront treatment of patients with newly
diagnosed glioblastoma multiforme: Safety and efficacy assessment.
Int J Radiat Oncol Biol Phys. 100:1195–1203. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu H, Wan C, Ding Y, Han R, He Y, Xiao J
and Hao J: PR-957, a selective inhibitor of immunoproteasome
subunit low-MW polypeptide 7, attenuates experimental autoimmune
neuritis by suppressing Th17-cell differentiation and
regulating cytokine production. FASEB J. 31:1756–1766. 2017.
View Article : Google Scholar : PubMed/NCBI
|
